SITE008-0072

withdrawn

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-05-25

AEs

Serious

Dropout signal

–

Adverse events

severe assessed

Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-07-24 (study day 53); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-09-19 (study day 110); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-16 (study day 137); relationship: N

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 182); relationship: Y

moderate assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-07-04 (study day 398); relationship: not assessed

severe assessed

Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-09-09 (study day 465); relationship: N

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-02-22 (study day 631); relationship: not assessed

severe assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-05-29 (study day 728); relationship: Y

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-08-01 (study day 792); relationship: Y

Data queries

No data queries.